Arsenic Trioxide as a Vascular Disrupting Agent: Synergistic Effect with Irinotecan on Tumor Growth Delay in a CT26 Allograft Model

MLA

Jong Cheo Lee, et al. “Arsenic Trioxide as a Vascular Disrupting Agent: Synergistic Effect with Irinotecan on Tumor Growth Delay in a CT26 Allograft Model.” Translational Oncology, vol. 6, no. 1, Feb. 2013, pp. 83–91. EBSCOhost, https://doi.org/10.1593/tlo.12322.

APA

Jong Cheo Lee, Ho Yong Lee, Chang Hoon Moon, Seung Ju Lee, Won Hyeok Lee, Hee Jeong Cha, Sungchan Park, Young Han Lee, Hyun Jin Park, Ho-Taek Song, & Young Joo Min. (2013). Arsenic Trioxide as a Vascular Disrupting Agent: Synergistic Effect with Irinotecan on Tumor Growth Delay in a CT26 Allograft Model. Translational Oncology, 6(1), 83–91. https://doi.org/10.1593/tlo.12322

Chicago

Jong Cheo Lee, Ho Yong Lee, Chang Hoon Moon, Seung Ju Lee, Won Hyeok Lee, Hee Jeong Cha, Sungchan Park, et al. 2013. “Arsenic Trioxide as a Vascular Disrupting Agent: Synergistic Effect with Irinotecan on Tumor Growth Delay in a CT26 Allograft Model.” Translational Oncology 6 (1): 83–91. doi:10.1593/tlo.12322.